Ravi Kaiwar, MBA, Ph.DBusiness Development Consultant Ravi has been with OXiGENE since 2011 to lead the business development efforts. He has been consulting for companies focused on drug development for cancer, autoimmune and infectious diseases. Ravi has over 18 years of experience in the industry, both as an R&D scientist as well as a business development professional. Most recently, he was Senior Director at Novacea (oncology) prior to engaging in independent consulting in 2009, where he was instrumental in scouting, screening, evaluating and closing several transactions including a transformational global collaboration with Schering Plough valued at $500 M for the company’s Phase III drug candidate. Prior to Novacea, Ravi was at Maxygen where he was responsible for business development activities for the vaccines business unit; during his tenure at Maxygen, he established collaborations with USAID, Naval Research Center and the NIAID for several vaccine programs. Ravi started his careen in the industry as a scientist at Aviron (later acquired by MedImmune and Astra Zeneca) leading the program on genital herpes vaccine development and contributed to the development of FluMist® and CMV vaccine candidates. Ravi holds PhD in Virology from the Post-graduate Institute of Medical Education and Research, Chandigarh, India and MBA from San Jose State University.
|
